Immunoprecise Operating Income from 2010 to 2024
| IPA Stock | USD 0.56 0.01 1.75% |
Operating Income | First Reported 1997-01-31 | Previous Quarter -3.9 M | Current Value -4.6 M | Quarterly Volatility 1.8 M |
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise Antibodies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 M, Interest Expense of 18.1 K or Total Revenue of 25.7 M, as well as many indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.87 or Days Sales Outstanding of 0.41. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules.
Immunoprecise | Operating Income |
Latest Immunoprecise Antibodies' Operating Income Growth Pattern
Below is the plot of the Operating Income of Immunoprecise Antibodies over the last few years. Operating Income is the amount of profit realized from Immunoprecise Antibodies operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Immunoprecise Antibodies is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Immunoprecise Antibodies' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunoprecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Immunoprecise Operating Income Regression Statistics
| Arithmetic Mean | (6,157,042) | |
| Geometric Mean | 1,456,818 | |
| Coefficient Of Variation | (126.29) | |
| Mean Deviation | 5,946,756 | |
| Median | (4,094,000) | |
| Standard Deviation | 7,775,622 | |
| Sample Variance | 60.5T | |
| Range | 26.3M | |
| R-Value | (0.82) | |
| Mean Square Error | 21.8T | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | (1,418,366) | |
| Total Sum of Squares | 846.4T |
Immunoprecise Operating Income History
About Immunoprecise Antibodies Financial Statements
Immunoprecise Antibodies stakeholders use historical fundamental indicators, such as Immunoprecise Antibodies' Operating Income, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immunoprecise Antibodies' assets and liabilities are reflected in the revenues and expenses on Immunoprecise Antibodies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -13.7 M | -13.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Check out the analysis of Immunoprecise Antibodies Correlation against competitors. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.